Sleep Clinical Trial
Official title:
Effect of Ketone Ester Supplementation on Sleep and Recovery in Hypoxia
NCT number | NCT06060093 |
Other study ID # | S67089 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 20, 2023 |
Est. completion date | March 31, 2023 |
Verified date | September 2023 |
Source | KU Leuven |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study specifically aims to elucidate the effects of IEK on sleep and recuperation in hypoxia, after training in normoxia. These conditions are in line with the widely applied live-high train-low strategy. Moreover, blood and tissue oxygenation status, as well as cerebral blood flow and cognitive function will be assessed.
Status | Completed |
Enrollment | 13 |
Est. completion date | March 31, 2023 |
Est. primary completion date | March 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent must be obtained prior to any experimental procedures 2. Males between 18 and 35 years old 3. Recreational or competitive cyclists performing regular cycling training sessions with an average training volume of more than 6 hours per week 4. Good health status confirmed by a medical screening 5. Body Mass Index (BMI) between 18 and 25 6. Normal sleep pattern as assessed by the Pittsburgh Sleep Quality Index 7. Moderate sleep chronotype (extreme morning and evening chronotypes will be excluded), assessed by the Horne and Östberg questionnaire Exclusion Criteria: 1. Any kind of injury/pathology that is a contra-indication for hypoxic exposure and/or to perform high-intensity exercise, evaluated by a sport medical screening 2. Intake of any medication or nutritional supplement that is known to affect exercise, performance or sleep. Intake will be assessed during recruitment and the sport medical screening. 3. Intake of analgesics, anti-inflammatory agents, or supplementary anti-oxidants, from 2 weeks prior to the start of the study. 4. Recent residence or training under hypoxia; more than 7 days exposure to altitude > 1500m during the last 3 months preceding the study. 5. Night-shifts or travel across time zones in the month preceding the study 6. Blood donation within 3 months prior to the start of the study 7. Smoking 8. More than 3 alcoholic beverages per day 9. Pre-existing, diagnosed psychiatric conditions or diagnosed anxiety 10. Excessive daytime sleepiness as assessed by the Epworth scale 11. Depression or anxiety as assessed by the Beck Depression Inventory and Beck Anxiety Inventory. Only a score in the range of 'normal ups and downs' (score 1-10) for depression or 'minimal anxiety' (score 0-7) for anxiety are tolerated. 12. History of addiction or excessive caffeine/alcohol consumption assessed by a questionnaire 13. Any other argument to believe that the subject is unlikely to successfully complete the full study protocol |
Country | Name | City | State |
---|---|---|---|
Belgium | KU Leuven | Leuven | Vlaams-Brabant |
Lead Sponsor | Collaborator |
---|---|
KU Leuven |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Duration of different sleep stages | Measured using polysomnography | Throughout the entire duration of the night, up to 9 hours after individual bedtime | |
Primary | Exercise performance | Measured as the average power output (W) during a 30 minutes time trial | 30 minutes on the second morning of the protocol | |
Primary | Change in nocturnal oxygen saturation | Measured using pulse oximetry | Throughout the entire duration of the night, up to 9 hours after individual bedtime | |
Primary | Absolute amount of nocturnal urinary catecholamine excretion | Measured using ELISA of collected nocturnal urine | Subjects empty bladder before sleep and urine will be collected throughout the entire duration of the night, up to 9 hours after individual bedtime and in the morning immediately after waking up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Recruiting |
NCT06079853 -
Nurse Suicide: Physiologic Sleep Health Promotion Trial
|
N/A | |
Completed |
NCT05017974 -
Research on Improving Sleep During Pregnancy
|
N/A | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT04513743 -
Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ
|
N/A | |
Completed |
NCT03251274 -
Bath Machine on Sleep Quality in Nursing Home
|
N/A | |
Completed |
NCT04102345 -
Lavender vs Zolpidem Sleep Quality During Diagnostic PSG
|
Early Phase 1 | |
Completed |
NCT03725943 -
Comparison of Dreem to Clinical PSG for Sleep Monitoring in Healthy Adults
|
N/A | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT04562181 -
Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index
|
N/A | |
Completed |
NCT05102565 -
A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers
|
N/A | |
Completed |
NCT05576844 -
Ai Youmian (Love Better Sleep) for People Living With HIV
|
N/A | |
Completed |
NCT04688099 -
Synovial Fluid Sleep Study
|
||
Recruiting |
NCT04171245 -
Prescribing Laughter for Sleep and Wellbeing in UAE University Students
|
N/A | |
Completed |
NCT03758768 -
The Effects of a Blue Monochromatic Light Intervention on Evening-type Individuals' Sleep and Circadian Rhythms
|
N/A | |
Completed |
NCT03163498 -
Evaluation of Sleep Pattern and Mood Profile in Hypertensive Patients
|
||
Completed |
NCT04093271 -
Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep
|
Phase 1 | |
Completed |
NCT03673397 -
The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression
|
N/A | |
Completed |
NCT04120363 -
Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations
|
Phase 4 |